The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Enzastaurin (ENZ) before and concomitant with radiation therapy (RTX) followed by ENZ maintenance therapy in patients with newly diagnosed glioblastoma (GBM) without hypermethylation of the O6-methylguanyl DNA-methyltransferase (MGMT) promoter: A multicenter, open-label, uncontrolled phase II study.
W. Wick
Consultant or Advisory Role - Antisense Pharma; Lilly; Merck; Roche; Schering-Plough
J. Steinbach
Consultant or Advisory Role - Roche; Schering-Plough
Honoraria - Schering-Plough
Research Funding - Merck; Novartis
S. E. Combs
No relevant relationships to disclose
M. Platten
No relevant relationships to disclose
C. Hartmann
Research Funding - Lilly
F. K. Wenz
Consultant or Advisory Role - Lilly
U. Boecker
Employment or Leadership Position - Lilly
C. Stoffregen
Employment or Leadership Position - Lilly
Stock Ownership - Lilly